The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers.Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.

    There was atime when this revered organization ranked among the lowest in the country in this area. Within ten years, however, it had climbed to among the highest and has emerged as the thought leader in the space.How did Cleveland Clinic turn itself around so effectively and so quickly?More important, how can you do the same with your organization?In gripping, visceral, on-the ground fashion, Service Fanatics reveals the strategies and tactics the Clinic applied to become one of today's leading patient-experience healthcare organizations--methods that seamlessly translate to any business seeking to improveits customer experience. This strategic guide covers:How the Clinic's leaders redefined the concept of patient experience and developed a strategy to improve itCritical lessons learned regarding organization, recruitment, training, and measuring service excellenceWays in which the Clinic aligned its entire workforce around its Patients First strategyHow leaders improved the critical element of physician communicationRather than view patients simply as sick people who need treatment, Cleveland Clinic sees them also as important stakeholders in the organization's success. Patients are customers--who desire, pay for, and deserve the best possible care and experience during what is often a challenging time in their lives.Featuring customer service case studies, as well as invaluable insight from C-level executives at top corporations in various industries, Service Fanatics provides actionable lessons for any manager and business leader beyond healthcare.Whether you run a healthcare institution, nonprofit, or for-profit business, Service Fanatics will help you create the kind of customer experience that promises to transform your organization into an industry powerhouse.

    For each body system, broad coverage of anatomy, physiology, pathology, diagnostic procedures, treatment procedures, and pharmacology is provided. The author emphasizes both terms built from Latin and Greek word parts, and modern English terms, helping students develop a full working word part vocabulary they can use to interpret any new term. This edition contains many new terms, and has been reorganized for more efficient learning. To eliminate confusion, Word Building tables have been removed from each chapter and the terms have been distributed throughout the pathology, diagnostic procedure, and treatment procedure tables, where they are more immediately relevant to students. Note: This ISBN is just the standalone book, if the customer wants the book/access card order the ISBN below; 133962032 / 9780133962031 Medical Terminology: A Living Language PLUS MyMedicalTerminologyLab with Pearson etext -- Access Card Package Package consists of: 0132843471 / 9780132843478 Medical Terminology: A Living Language 0133936236 / 9780133936230 MyMedicalTerminologyLab with Pearson etext - Access Card - Medical Terminology A Living Language

    With extensive treatment of the heart of epidemiology-from study designs to descriptive epidemiology to quantitative measures-this reader-friendly text is accessible and interesting to a wide range of beginning students in all health-related disciplines. A unique focus is given to real-world applications of epidemiology and the development of skills that students can apply in subsequent course work and in the field. The text is also accompanied by a complete package of instructor and student resources available through a companion Web site.

    

    Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.In Science Lessons, Gordon Binder—CEO and chairman during 1988-2000—describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges—such as managing creative employees, navigating the IPO process, and protecting intellectual property.This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great—offering valuable lessons for all companies.

    When there aren’t enough of them, or they aren’t working properly, chronic diseases can manifest and persist. From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, stem cell therapy has helped when standard medicine failed. Many of them had lost hope. These are their stories. Neil H Riordan, author of MSC: Clinical Evidence Leading Medicine’s Next Frontier, the definitive textbook on clinical stem cell therapy, brings you an easy-to-read book about how and why stem cells work, and why they’re the wave of the future. “Neil takes readers on a riveting journey through the past, present and future of stem cell therapy. His well-researched, educational and entertaining book could change your life. I highly recommend it.” Tony Robbins, NY Times #1 Bestselling Author 100 years old will soon become the new 60. Stem cells are a key therapeutic to enable this future. Dr. Riordan’s book is your guide to why this is true and how you will benefit. A must read for anyone who cares about extending their healthy lifespan.” Peter H. Diamandis, MD; Founder, XPRIZE & Singularity University; Co-Founder, Human Longevity, Inc.; Author of NY Times Best Sellers Abundance and Bold

    But by this point in her startling book, Dangerous Doses, readers are already on a first-name basis with the five investigators involved in breaking the case. These five -- drug inspectors, Miami detectives, and a former cop -- had marshaled their forces to protect Floridians from adulterated, expired, or mishandled prescription drugs, and Eban spent two and a half years with them, weaving together her story of drug supply corruption, not merely in Florida but throughout the nation.Americans spend nearly $216 billion to fill over 3 billion prescriptions a year, and most believe that what they ingest, inject, or apply topically travels from the drug maker to their pharmacy through pristine labs and warehouses filled with men in white coats. But Eban discovered a different route, one driven by middlemen: wholesalers who sell diverted, degraded, and expired medicine traded by felons and accompanied by falsified paperwork. The truth is chilling and complex, but Eban's intelligent writing, careful plotting, and dogged reporting make for a suspenseful and shocking read, and she offers a battle-ready road map for combating the problem, including excellent practical advice for consumers. (Fall 2005 Selection)

    Margaret I. Cuomo is inspired to seek out new strategies for waging a smarter war on cancer.This year, about 1.6 million new cases of cancer will be diagnosed and more than 1,500 people will die "per day." We've been asked to accept the disappointing strategy to "manage cancer as a chronic disease." We've allowed pharmaceutical companies to position cancer drugs that extend life by just weeks and may cost $100,000 for a single course of treatment as breakthroughs. Where is the bold leadership that will transform our system from treatment to prevention? Have we forgotten the mission of the National Cancer Act of 1971 to "conquer cancer"?Through an analysis of more than 40 years of medical evidence and interviews with the top cancer researchers, drug company executives, and health policy advisers, Dr. Cuomo reveals intriguing answers to these questions. She shows us how all cancer stakeholders--the pharmaceutical industry, the government, physicians, and concerned Americans--can change the way we view and fight cancer in this country.

    You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.

    Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

    Although necessary health care should be available to all who need it, he says, the current health-care debate assumes that everyone requires massive amounts of expensive care to stay healthy. Hadler urges that before we commit to paying for whatever pharmaceutical companies and the medical establishment tell us we need, American consumers need to adopt an attitude of skepticism and arm themselves with enough information to make some of their own decisions about what care is truly necessary. Each chapter of Worried Sick is an object lesson regarding the uses and abuses of a particular type of treatment, such as mammography, colorectal screening, statin drugs, or coronary stents. For consumers and medical professionals interested in understanding the scientific basis for Hadler's arguments, each topical chapter has an accompanying source chapter in which Hadler discusses the medical literature and studies that inform his critique. According to Hadler, a major stumbling block to rational health-care policy in the United States is contention over the very concept of what constitutes good health. By learning to distinguish good medical advice from persuasive medical marketing, consumers can make better decisions about their personal health and use that wisdom to inform their perspectives on health-policy issues.

    It Combines Comprehensive Medical Content With Dynamic New Features And Interactive Technology To Better Support Instructors And To Help Prepare Students For The Field. An Interactive Skills DVD Is Also Packaged Free With Each Copy Of The Text.

    These areas of knowledge have converged into a modern theory of epidemiology that has been slow to penetrate into textbooks, particularly at the introductory level. Epidemiology: An Introduction closes the gap. It begins with a brief, lucid discussion of causal thinking and causal inference and then takes the reader through the elements of epidemiology, focusing on the measures of disease occurrence and causal effects. With these building blocks in place, the reader learns how to design, analyze and interpret problems that epidemiologists face, including confounding, the role of chance, and the exploration of interactions. All these topics are layered on the foundation of basic principles presented in simple language, with numerous examples and questions for further thought.

    Its organization and thoroughness are unsurpassed, putting it above similar review books. Students who thoroughly read this book should have no trouble successfully completing their psychiatry clerkship and passing the shelf exam. As course director for the core psychiatry clerkship at my institution, I will recommend this book to students."--Doody's Review Service"First Aid for the Psychiatry Clerkship" gives you the core information needed to impress on the wards and pass the psychiatry clerkship exam. Written by students who know what it takes to succeed, and based on the national guidelines for the psychiatry clerkship, the book is filled with mnemonics, ward and exam tips, tables, clinical images, algorithms, and newly added mini-cases.Features Completely revised based on the psychiatry clerkship's core competencies Written by medical students who passed and reviewed by faculty for accuracy NEW integrated mini-cases illustrate classic patient presentations and/or commonly tested scenarios NEW illustrations and management algorithms Updated throughout with enhanced sections on medications, depression/anxiety, and child psychiatry Helps students hone in on the most important concepts for the clerkship and the examThe content you need to ace the clerkship: Section I: How to Succeed in the Psychiatry Clerkship Section II: High-Yield Facts; Examination and Diagnosis; Psychotic Disorders; Mood Disorders; Anxiety and Adjustment Disorders; Personality Disorders; Substance-Related Disorders; Cognitive Disorders; Geriatric Disorders; Psychiatric Disorders in Children; Dissociative Disorders; Somataform and Factitious Disorders; Impulse Control Disorders; Eating Disordes; Disorders; Sleep Disorders; Sexual Disorders; Psychtherapies; Psychopharmacology; Legal Issues; Section III: Awards and Opportunities.